T ype 2 diabetes mellitus (T2DM), excess weight, and obesity are increasing in prevalence at alarming rates. [1] [2] [3] Concurrent with the increased prevalence is increased risk of morbidity and mortality. A healthy diet and exercise in conjunction with antidiabetes medications can help lower glucose concentration in patients with T2DM. Because these patients are at increased risk of cardiovascular (CV) morbidity and mortality, however, treatment strategies should address the CV risk factors, including blood pressure (BP), lipids, and body weight, as well as glycemic aspects of the disease.
To help clinicians manage the complex issues in treating patients with T2DM, this article presents an overview of patient and treatment perspectives relevant to overweight/obesity and CV disease (CVD). It includes an examination of the latest guidelines and algorithms for the management of T2DM, which continue to be updated and modifi ed.
   T2DM, WEIGHT GAIN OR OBESITY, AND CV RISK:
A CHALLENGING TRIAD Despite therapeutic advances in the diagnosis and treatment of diabetes and CVD over the last decade, the estimated number of persons in the United States older than 35 years with self-reported diabetes (with T2DM accounting for 90% to 95% of diagnosed cases) and CVD has increased from 4.2 million in 1997 to 5.7 million in 2005. 3, 4 The CV risk for patients with T2DM who have not had a CV event such as a myocardial infarction (MI) is similar to that of individuals without diabetes who have had a prior MI. 5 Patients with T2DM have nearly double the mortality of those without the disease. 6 Adding to their risk, about 80% of patients with T2DM are overweight or obese, conditions associated with worsened insulin resistance and increased CV risk and disease burden. 7, 8 Even a modest weight gain (5 kg) may increase the risk of coronary heart disease (CHD) by 30%, while associated changes in lipids and BP can increase the risk by another 20%.
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to control glycemia in patients with T2DM, and both are diffi cult to achieve. Data from a recent nationwide Norwegian survey showed that only 13% of patients with T2DM achieved study-defi ned target levels; ie, glycosylated hemoglobin (HbA1c) less than 7.5%, BP less than 140/85 mm Hg, and total cholesterol/high-density lipoprotein (HDL-C) ratio less than 4.0. 10    BENEFITS OF MANAGING GLYCEMIA, WEIGHT REDUCTION, AND CV RISK FACTORS Several large studies, many ongoing, are generating data on the relationships among glycemia, weight reduction, and CV risk. It is well established that individuals with T2DM need aggressive risk factor reduction (glucose control, blood pressure management, and treatment of dyslipidemia) to optimize outcomes. However, characterization of the benefi ts of various components of risk factor reduction, particularly over many years, is only now occurring.
Results from the United Kingdom Prospective Diabetes Studies (UKPDS) showed the benefi ts and risks of pharmacologic glycemic control-essentially monotherapy with insulin or a sulfonylurea-compared with conventional dietary therapy in reducing diabetic complications in patients with newly diagnosed T2DM. In UKPDS 33, both insulin and sulfonylureas (intensive treatment) reduced the risk of microvascular end points (retinopathy, nephropathy) in patients whose median HbA1c was lowered to 7.0% at 10 years of follow-up, compared with patients who reached an HbA1c of 7.9%. However, intensive glycemic control did not translate into a statistically signifi cant reduction in macrovascular complications, including MI, stroke, CVD, and death. Additionally, patients assigned to insulin had greater weight gain (+4.0 kg) than did patients assigned to receive the sulfonylurea chlorpropamide (+2.6 kg) or glyburide (+1.7 kg) (P < .01).
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The UKPDS showed that intensive treatment with metformin reduced the risk of T2DM-related end points compared with conventional treatment (primarily diet alone) in overweight patients. 12 Although there were fewer patients in the metformin-treated subset (n = 342) than in the conventional treatment cohort, a secondary analysis showed that metformin was associated with less weight gain and fewer hypoglycemic episodes than either insulin or sulfonylurea therapy. 12 Since HbA1c levels in the treatment groups were equal, the additional benefi ts seen with metformin in overweight patients with T2DM were not based solely on glycemic control.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial involved 10,000 individuals with T2DM. The primary outcome measure was a composite of CV events. The intensively treated group was controlled to a target HbA1c of less than 6.0%, with most patients receiving insulin. The trial was terminated early because an increased risk of sudden death was observed. 13 A similar study, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modifi ed Release Controlled Evaluation (ADVANCE), evaluated more than 11,000 patients with T2DM, starting with a sulfonylurea-based regimen. In this study, there was no reduction in macrovascular events, but there was a reduction in nephropathy in the intensively treated group. 14 In both studies, hypoglycemia and weight gain were more frequent in intensively treated patients; and in ACCORD, there were more episodes of severe hypoglycemia in the intensive-treatment group. 13, 14 The Veterans Affairs Diabetes Trial (VADT) evaluated the effect of intensive glucose control on CVD in 1,791 patients (mean age, 60 years) with poorly controlled T2DM (average duration, 11.5 years). The primary end points included MI, stroke, new or worsening congestive heart failure (CHF), limb amputation, and invasive intervention for coronary or peripheral arterial disease. The hazard ratio for these end points in the intensive-treatment group was 0.88 (95% confi dence interval [CI], 0.74 to 1.05). 15, 16 Specifi cally, the following benefi cial effects were achieved:
• HbA1c reduced by Ϫ1.0% to Ϫ2.5% in absolute units, • systolic BP (SBP) reduced by Ϫ4 to Ϫ7 mm Hg, • diastolic BP (DBP) reduced by Ϫ7 to Ϫ8 mm Hg, • low-density lipoprotein cholesterol (LDL-C) reduced by Ϫ27 to Ϫ28 mg/dL, • triglycerides reduced by Ϫ44 to Ϫ50 mg/dL, and • HDL-C increased by 4 to 5 mg/dL. Despite these benefi ts, body weight increased approximately 9 to 18 lb (4 to 8 kg) during therapy. 15 Since overweight and obesity are independent risk factors for CHD and CVD in patients with T2DM, 17 weight management is an integral component in treatment. In the Action for Health in Diabetes (Look AHEAD) trial, an intensive exercise and weight-loss program resulted in clinically signifi cant (P < .001) weight loss at 1 year in patients who had T2DM and a body mass index (BMI) greater than 25 kg 2 /m (> 27 kg 2 /m if receiving insulin). 18 When compared with patients who received less structured, infrequent support and minimal education about diabetes, participants in the intensive program showed more weight loss, improved glucose control, decreased CV events, and reduced medicine use. The Look AHEAD trial is currently evaluating whether these improvements will continue to result in lower CV risk.
   PATIENT ADHERENCE AND SATISFACTION
It is often challenging for patients with T2DM to adhere to their treatment regimens. The Diabetes Attitude,
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Wishes, and Needs (DAWN) study examined psychosocial barriers to self-care in patients with diabetes and found that while 78% of patients with T2DM adhered to their medications, only 39% achieved complete success in at least two-thirds of their self-care domains. 19 A multicenter, randomized, clinical trial examined the correlates of treatment satisfaction, including body weight, on patients' appraisal of treatment satisfaction with injectable insulin. The 14.5% of patients who experienced a reduction in BMI reported systematic improvement in treatment satisfaction. 20 Similarly, a cross-sectionally designed study (n = 99) that analyzed the interrelation of adherence, BMI, and depression in adults with T2DM found that patients with higher BMI and poor adherence also had depression, which was mediated by lower self-effi cacy perceptions and increased diabetes symptoms. 21 The results from these studies show a clear relationship between adherence with treatment regimens and achievement of HbA1c goals. 22 
   RECENT DEVELOPMENTS IN T2DM MANAGEMENT:
STRATEGIES TO REDUCE CV RISK Because excess weight and obesity are prominent features of T2DM, it is important to use an antidiabetes agent that does not induce unnecessary weight gain (particularly central weight gain, which is thought to be most atherogenic). 23 Metformin, considered the fi rstline agent for treatment of T2DM, is generally weight neutral with a low level of hypoglycemia. 24, 25 Sulfonylureas, insulin, and thiazolidinediones (TZDs) are all associated with weight gain, although newer-analogue insulins may cause less weight gain than older agents. TZDs, especially pioglitazone, are associated with improvements in long-term beta-cell function and CV risk factors despite weight gain. 26, 27 The newer antidiabetes agents belong to the dipeptidyl peptidase-4 (DPP-4) inhibitor and the glucagonlike peptide-1 (GLP-1) receptor agonist therapeutic classes and have been shown to be either weight neutral (DPP-4 inhibitors) or to cause weight loss (GLP-1 receptor agonists). which induces glucose-dependent insulin secretion after food intake by binding to specifi c receptors on pancreatic beta cells, suppresses postprandial glucagon from pancreatic alpha cells, reduces postprandial plasma glucose (PPG) concentrations by delaying gastric emptying, and diminishes appetite. 28 The diminished secretion of GLP-1 in T2DM 30, 31 has led to the development of two different treatment approaches. 28 Since GLP-1 is rapidly degraded by DPP-4, GLP-1 receptor agonists have been developed to resist DPP-4 inactivation while exhibiting many of the actions of endogenous incretin hormones. 28, 29 DPP-4 inhibitors function as incretin enhancers by protecting endogenous GLP-1 and glucose-dependent insulinotropic peptide, another incretin, from enzymatic breakdown. [31] [32] [33] Unlike the GLP-1 receptor agonists, which are administered subcutaneously (SC), DPP-4 inhibitors are administered orally.
Obesity and the incretin effect
A study in healthy subjects and patients with T2DM demonstrated that glucose tolerance and obesity independently impair the incretin effect, resulting in impaired insulin secretion and glucagon suppression. 34 Obesity is considered a subclinical infl ammatory condition that releases chemokines, leading to insulin resistance. Figure 2 illustrates the interaction between obesity, infl ammation, and insulin resistance. 35 Two recent studies showed that surgically induced weight loss enhances the physiologic "incretin effect." In one study, obese individuals with T2DM whose weight loss was secondary to bariatric surgery combined with caloric restriction showed improved insulin sensitivity, improved carbohydrate metabolism, and elevated levels of adiponectin and GLP-1, all of which may reduce the incidence of T2DM. 36 In the other study, bariatric surgery in morbidly obese individuals with T2DM improved insulin secretion and ameliorated insulin resistance. 28 Sitagliptin has been compared with placebo as monotherapy and has been studied in combination with other therapies.
In an 18-week study, sitagliptin monotherapy, 100 and 200 mg QD, signifi cantly reduced HbA1c compared with placebo (placebo-subtracted HbA1c reduction, Ϫ0.60% and Ϫ0.48%, respectively) in patients with T2DM. Sitagliptin also signifi cantly decreased fasting plasma glucose (FPG) concentration relative to placebo. 38 Twelve weeks of sitagliptin monotherapy at dosages of 5, 12.5, 25, and 50 mg BID led to signifi cant (P < .001) reductions in HbA1c compared with placebo. Sitagliptin also produced signifi cant reductions in FPG and mean daily glucose concentrations across the doses studied. 39 Similar results were reported in other 12-week studies: 50 mg BID and 100 mg QD sitagliptin monotherapy signifi cantly (P < .05) reduced HbA1c Ϫ0.39% to Ϫ0.56% and FPG concentration Ϫ11.0 to Ϫ17.2 mg/dL compared with placebo 40 ; sitagliptin 100 mg QD compared with placebo produced a least-squares mean change from baseline HbA1c of Ϫ0.65% versus 0.41% (P < .001) and FPG of Ϫ22.5 versus 9.4 mg/dL (P < .001). 41 Sitagliptin also has been studied in combination with other therapies. After 24 weeks, sitagliptin combined with pioglitazone signifi cantly reduced HbA1c by Ϫ0.70% and FPG by Ϫ17.7 mg/dL (P < .001 for both) compared with placebo. 42 In another 24-week study, 100 mg sitagliptin QD signifi cantly improved glycemic control and beta-cell function (P < .05 for both) in patients with T2DM who had inadequate glycemic control with glimepiride or glimepiride plus metformin. 43 In addition to signifi cantly reducing HbA1c, sitagliptin 100 and 200 mg QD produced only small differences in body weight relative to placebo: least-squares mean change from baseline for sitagliptin 100 mg was Ϫ0.7 kg (95% CI, Ϫ1.3 to Ϫ0.1) and for 200 mg was Ϫ0.6 kg (95% CI, Ϫ1.0 to Ϫ0.2); for placebo it was Ϫ0.2 kg (95% CI, Ϫ0.7 to 0.2). 38 These fi ndings were consistent with those from another 24-week monotherapy study where sitagliptin produced weight loss of up to Ϫ0.2 kg 44 and a 30-week study of sitagliptin added to ongoing metformin therapy. In the latter study, both sitagliptin and placebo resulted in weight reductions of Ϫ0.5 kg. 45 The effects of sitagliptin on lipids and BP have been reported in clinical studies in patients with and without T2DM. In one study of patients with T2DM, the addition of sitagliptin to metformin increased total cholesterol (+8.1 mg/dL), LDL-C (+9.2 mg/dL), and HDL-C (+1.8 mg/dL) but lowered triglyceride (Ϫ14.5 mg/dL) after 18 weeks of treatment (24-week data). 46 Data from a small (n = 19) study in nondiabetic patients with mild to moderate hypertension showed that sitagliptin produced small reductions (Ϫ2 to Ϫ3 mm Hg) in 24-hour ambulatory BP measurements. 47 Another DPP-4 inhibitor, saxagliptin, with effi cacy similar to that described for sitagliptin, was recently approved by the US Food and Drug Administration (FDA) for treatment of T2DM.
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GLP-1 receptor agonists
Many of the GLP-1 receptor agonists developed or under development have glucoregulatory effects similar to GLP-1 but are resistant to degradation by DPP-4. 28 Exenatide, an exendin-4 receptor agonist, has compared favorably with sitagliptin and with insulin analogues. Long-acting (once-weekly and once-daily) GLP-1 receptor agonists are under development.
In a 2-week, head-to-head study in metformin-treated patients with T2DM, exenatide had a greater effect than sitagliptin in lowering PPG and was more potent in increasing insulin secretion and reducing postprandial glucagon secretion. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. 49 In two studies of patients treated with exenatide, on a background of either metformin alone or metformin plus a sulfonylurea, patients who received metformin lost more weight (Ϫ1.6 to Ϫ2.8 kg; P .01) and experienced more signifi cant decreases from baseline HbA1c (Ϫ0.4% to Ϫ0.8%; P < .002) at 30 weeks than did patients who received placebo. 50, 51 In a 16-week trial 
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of exenatide in patients previously treated with a TZD with or without metformin, exenatide reduced HbA1c Ϫ0.98%, fasting blood glucose Ϫ1.69 mmol/L, and body weight Ϫ1.51 kg. 52 When compared with insulin analogues, exenatide has been associated with weight loss (~ Ϫ3 kg) while the insulin analogues were associated with weight gain (~ +3 kg). 53 After 26 weeks, body weight decreased Ϫ2.3 kg with exenatide and increased +1.8 kg with insulin glargine. 54 Similar results were found in a crossover noninferiority trial, where the least-squares mean difference in weight change was signifi cantly (P < .001) different (2.2 kg) between the treatments. 55 When exenatide was compared with insulin aspart in an open-label, noninferiority trial, there was a between-group difference in weight of Ϫ5.4 kg after 52 weeks. 32 Exenatide has also demonstrated these benefi ts in open-label extension studies. After 2 years, mean HbA1c reductions of Ϫ1.1% from baseline were sustained (P < .05), and weight loss of Ϫ4.7 kg was maintained (P < .001). 56 After 82 weeks, similar HbA1c decreases (Ϫ1.1%) and weight loss (Ϫ4.4 kg) were exhibited. 57 Even after 3 years, these benefi ts were maintained in patients who remained on the drug (HbA1c reduction from baseline, Ϫ1.0%; weight loss, Ϫ5.3 kg [P < .0001 for both]). 58 Long-acting formulations of GLP-1 receptor agonists are in clinical development; two of these are onceweekly exenatide and once-daily liraglutide. Exenatide once weekly has the advantage of less frequent dosing and has elicited greater reductions in HbA1c than exenatide BID. After 15 weeks of once-weekly administration, the 0.8-mg formulation reduced HbA1c Ϫ1.4% and the 2-mg formulation reduced it Ϫ1.7% (P < .0001 for both compared with placebo). Body weight was lowered Ϫ3.8 kg (P < .05 compared with placebo) with the 2-mg formulation. 59 Compared with exenatide BID, exenatide 2 mg once weekly showed greater reductions in HbA1c (Ϫ1.9% vs Ϫ1.5%; P = .0023) after 30 weeks of therapy. 60 In a 1-year noncomparative trial, treatment with exenatide once weekly improved HbA1c (Ϫ2.0%) and weight (Ϫ4.1 kg), as well as BP and lipid profi les compared with baseline. 61 Liraglutide, a once-daily human analogue GLP-1 receptor agonist, is under review by the FDA. 28 In a 26-week study of patients with T2DM, liraglutide was associated with reductions in HbA1c (mean, Ϫ1.04%; P = 0.067 compared with insulin) and body weight (mean, Ϫ2.5 kg; P < .001 compared with insulin) at dosages of 0.6 to 1.8 mg/day SC. Liraglutide produced a decline in SBP from 0.6 to 3 mm Hg but was not associated with a decrease in DBP. 62 In a 52-week study comparing liraglutide with glimepiride monotherapy, liraglutide 1.2 mg was associated with an HbA1c reduction of Ϫ0.84% (P = .0014) and the 1.8-mg dose with a reduction of Ϫ1.14% (P < .0001) compared with Ϫ0.51% for glimepiride. SBP decreased Ϫ0.7 mm Hg with glimepiride compared with Ϫ2.1 mm Hg for liraglutide 1.2 mg (P = .2912) and Ϫ3.6 mm Hg for liraglutide 1.8 mg (P < .0118). Mean DBP fell slightly but not signifi cantly in all treatment groups. 63 No effects on lipid parameters were reported in these two liraglutide studies.
The Liraglutide Effect and Action in Diabetes (LEAD-6) trial was undertaken to compare exenatide (10 g BID SC) and liraglutide (1.8 mg/day SC) as add-on therapy to metformin, a sulfonylurea, or a combination of both in 464 patients with T2DM. After 26 weeks of treatment, liraglutide was associated with a signifi cant reduction in HbA1c of Ϫ1.12%, compared with Ϫ0.79% with exenatide (P < .0001). Patients treated with liraglutide lost Ϫ3.2 kg while those on exenatide lost Ϫ2.9 kg. Among patients previously treated with metformin alone, there was a 1-kg difference in favor of liraglutide (P = NS).
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Safety profi le
All of the drugs discussed have potential adverse effects. Metformin continues to have a black box warning for lactic acidosis. 65 Sulfonylureas and insulin can cause hypoglycemia. TZDs can cause fl uid retention and, in rare cases, CHF (for which these drugs also carry a black box warning). 66, 67 TZDs also increase the risk of distal fracture. 66, 67 The most common side effects of exenatide are gastrointestinal, but there have been reported cases of pancreatitis, some of which have been fatal. 68, 69 It has been diffi cult to prove whether exenatide increases the risk of pancreatitis, as patients with T2DM are already at an increased (three-to fourfold) risk for this condition compared with persons who do not have T2DM. 69 Exenatide should not be used in patients with severe renal impairment or end-stage renal disease; it should be used with caution in patients who have undergone renal transplantation and in patients with moderate renal impairment.
The prescribing information for sitagliptin includes pancreatitis among the adverse reactions identifi ed during the drug's postapproval use. 70 As with exenatide, it is not fully known whether a true association exists between the agent and pancreatitis. However, since pancreatitis can occur in this patient population, it is recommended that abdominal pain be fully evaluated to rule out pancreatitis. Continued postmarketing surveillance is important for all of these agents.
  THE ROLE OF GUIDELINES
The American Association of Clinical Endocrinologists (AACE), 26 the American Diabetes Association (ADA), 71 and the ADA in conjunction with the European Association for the Study of Diabetes (EASD) 24 have recently revised their recommendations for the management of patients with diabetes. The guidelines are unanimous in setting a glycemic goal (HbA1c < 7.0% for the ADA, HbA1c 6.5% for the AACE) and advocating individualized care for a treatment goal of HbA1c lower than 6.0% in patients who stand to benefi t from near euglycemia without inducing severe hypoglycemia. 24, 26, 71 CVD is the major cause of morbidity and mortality associated with T2DM and is a source of increasing concern.
5 Accordingly, special consideration should be given to patients with coexisting CV risk factors, including hypertension and dyslipidemia. The ADA and the EASD advocate lifestyle modifi cation to decrease body weight and the concurrent initiation of metformin as fi rst-line therapy. 24 If that strategy is insuffi cient, then two tiers of treatment guide the choice of next steps 24 :
• Tier 1, in addition to metformin, includes the sulfonylureas and insulin. Although these are excellent glucose-lowering drugs, they are associated with weight gain, hypoglycemia, and no improvement in BP or lipid levels. They are relatively low in cost and have been used for many years. Their main drawback is evidence that despite their use, beta-cell failure continues unabated over time.
• Tier 2 treatments include pioglitazone and the GLP-1 receptor agonist exenatide. Consideration may be given to the use of pioglitazone or exenatide when hypoglycemia is of concern, with exenatide being preferred when weight loss is a major objective and HbA1c is close to target (< 8.0%). 24 Additionally, both the TZDs and exenatide probably help slow the rate of beta-cell failure, particularly if they are used early in the course of the disease. 72, 73 The AACE recommends different pharmacologic approaches based on HbA1c at diagnosis. 26 The American Heart Association and the ADA have issued a joint scientifi c statement on the primary prevention of CVD in patients with diabetes. 74 They advocate lifestyle management of body weight, nutrition, and physical activity. 74 In addition, they stress the need for attention to BP, lipid levels, and smoking status, and the use of antiplatelet agents in patients at increased CV risk (> 40 years of age and a family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria).
  CONCLUSION
T2DM, weight gain/obesity, and CV risk present a continuing challenge to patients and clinicians. Antidiabetes agents have varying degrees of evidence to support their effects on HbA1c, body weight, BP, and lipid levels. A better understanding of the pathophysiology of T2DM has led to the development of newer antidiabetes agents that target the fundamental defects of the disease. Evidence continues to accumulate for the improved benefi ts of glycemic control and weight loss in T2DM with GLP-1 receptor agonists such as exenatide currently having robust data in terms of benefi cial effects on weight and CV risk factors. As clinicians continue to incorporate this knowledge into their practice patterns, patient adherence and clinical outcomes are expected to improve. Newer agents, such as incretin-based therapies, address T2DM as well as other factors that increase cardiometabolic risk through their effects not only on glycemic control but on body weight, BP, and lipids.
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